



HAL
open science

Rapid assessment of estrogenic compounds by CXCL-test illustrated by the screening of the UV-filter derivative benzophenones.

Denis Habauzit, Catherine Martin, Gweneg Kerdivel, Farzad Pakdel

► To cite this version:

Denis Habauzit, Catherine Martin, Gweneg Kerdivel, Farzad Pakdel. Rapid assessment of estrogenic compounds by CXCL-test illustrated by the screening of the UV-filter derivative benzophenones.. Chemosphere, 2017, 173, pp.253-260. 10.1016/j.chemosphere.2017.01.037 . hal-01477205

HAL Id: hal-01477205

<https://univ-rennes.hal.science/hal-01477205>

Submitted on 27 Mar 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Rapid assessment of estrogenic compounds by CXCL-test illustrated by the**
2 **screening of the UV-filter derivative Benzophenones**

3 **Denis Habauzit^{*}, Catherine Martin, Gwenneg Kerdivel, Farzad Pakdel**

4 Institut de Recherche en Santé - Environnement - Travail (IRSET), Inserm U1085, TREC Team, University of
5 Rennes 1, Rennes, France

6

7 ***Corresponding author:**

8 Dr. Denis HABAUZIT

9 IRSET, Inserm U1085, University of Rennes 1, 35000 Rennes cedex, France.

10 Phone: +33-2 23 23 51 32

11 Fax: +33-2 23 23 67 94

12 E-mail: denis.habauzit@univ-rennes1.fr

13 farzad.pakdel@univ-rennes1.fr

14

15

16 **Abstract**

17 CXCL-test is a method that uses the estrogen-dependent secretion of the natural endogenous chemokine
18 CXCL12 to evaluate the estrogenic activity of molecules. CXCL12 chemokine is involved in the estrogen
19 dependent proliferation of breast cancer cells. Its measure is an indicator of cell proliferation and is used as an
20 alternative test to classical proliferation test.

21 Here we aimed to optimize this test, first to increase the number of tested molecules in a single assay and then to
22 decrease the number of intermediate steps. The optimized CXCL-test was finally used for the evaluation of the
23 estrogenic potency of emerging chemical pollutants: the UV filter benzophenones (BPs). The effect of BPs on
24 CXCL12 secretion was also validated by real time quantitative RT-PCR.

25 The optimized CXCL-test allowed a fast and direct assessment of estrogenic potency of molecules. The
26 estrogenic activities of benzophenones were characterized and divided in two groups. The first one contains
27 weak estrogenic compounds (BP, BP1, BP2, BP3, 234BP and 2344'BP). The second one contains medium
28 estrogenic compounds (4BP, 44'BP, BP8, THB).

29

30 **Highlights**

- 31
- CXCL-test optimization allows the assessment of several estrogenic chemicals in a single assay
 - Utilization of CXCL-test to measure estrogenic activity of benzophenones
 - Benzophenones have estrogenic activity in the μM range
- 32
- 33

34

35 **Keywords**

36 Estrogens, detection, CXCL-test, endocrine disrupting chemicals, benzophenone, xeno-estrogens

37 1. Introduction

38

39 Human activities, due to industrialization and to drugs consumption, have led to the increase of diverse
40 chemical releases in environment, especially in surface water. This increase is partially due to the incomplete
41 elimination of the contaminants in waste water treatment plan. Some of these chemicals evidenced unpredicted
42 endocrine disrupting activities. The main difficulty in this research area is that the disruption could occur in large
43 biological tissues, functions, pathways or proteins (Kerdivel et al., 2013a; Yoon et al., 2014). Therefore the
44 assessment of endocrine disrupting activity for many compounds was always performed *a posteriori* either after
45 several years of the use of compounds or because of an evidence of a health effect, such as the use of
46 Diethylstilbestrol or Bisphenol A. Moreover, the assessment is sometimes performed after the detection of a high
47 concentration of several compounds in environment linked with adverse effects in wildlife evidenced through
48 morpho-anatomical modifications or expression of feminine protein marker in male fish. Since, many comity or
49 regulations have aimed to develop early evaluation of the new chemical such as EDSTAC (now EDSP) and
50 Reach program. Several methods have been established over the last 3 decades in order to assess endocrine
51 disrupting chemical (EDC) activities, especially estrogenic activity (Leusch, 2008; Scholz et al., 2013). These
52 methods specifically target several critical points that have been identified in fundamental studies in the
53 endocrine function such as development of uterus (Isenhower et al., 1986), estrogen-induced proliferation of cell
54 lines (Soto et al., 1995), expression of estrogen-regulated genes (vitellogenin) (Flouriot et al., 1995) or molecular
55 interaction with transcription factors (Habauzit et al., 2007). But the evaluation of the estrogenic activity of a
56 molecule raises several questions about the relevance of the target, the considered material (organ, tissue, cells or
57 molecules), and the analysis time and cost.

58 CXCL12 is a cytokine coupled with two G protein coupled receptors (CXCR4 and CXCR7) that is
59 implicated in the proliferation and migration of breast cancer cells (Boudot et al., 2011). E2-induced CXCL12
60 expression and its impact on cell proliferation has then been illustrated by our team and others (Boudot et al.,
61 2011; Glace et al., 2009; Hall and Korach, 2003; Pattarozzi et al., 2008). Moreover, we have demonstrated that
62 CXCL12 secretion is an early indicator of estrogen-dependent proliferation of breast cancer cells (MCF7 and
63 T47D). The knowledge of estrogen-dependent regulation of this cytokine led to the development of a fast test for
64 the assessment of estrogenic effect of molecules (Habauzit et al., 2010). By using CXCL12 secretion for EDC-

65 evaluation, Hall and Korach demonstrated that some EDCs also induce growth of ovarian cancer cells through
66 the estrogen receptor (ER)-dependent induction of CXCL12 expression (Hall and Korach, 2013). CXCL-test is
67 faster (14 hours) than the classical proliferation test (5-7 days) and sensitive enough for the assessment of both
68 strong and weak estrogenic compounds.

69 Even if a lot of methods for the evaluation and the quantification of EDCs exist, few tests are using
70 natural endogenous genes expression with a low detection limit for the evaluation of the proliferative ability of
71 molecules. Moreover, due to the diversity of estrogenic compounds' actions and pathways, numerous methods
72 have to be developed for the entire evaluation of the molecule action. For that reason, we aimed to ameliorate
73 and optimize the CXCL-test by scaling it up to 96 wells plate and by reducing intermediate steps. To validate
74 these optimizations and illustrate their relevance for risk assessment, we assessed a new EDC family with
75 estrogen-like activity, the benzophenones. They are used in several cosmetic products and they possess
76 ultraviolet (UV) filter activities. Because of their lipophilic properties, they penetrate easily in bodies and can be
77 found in human fluid such as urine (Vela-Soria et al., 2014), women milk (Rodríguez-Gómez et al., 2014). The
78 diversity of benzophenone's use makes that large amount of these compounds are found in the waste water
79 treatment plant and constitute a risk for wildlife (Jurado et al., 2014). As the treatment plant eliminates only
80 partially these compounds, they are found to high concentration (up to mg/L) in rivers all over the world (Tsui et
81 al., 2014) and also in sediment (Gago-Ferrero et al., 2011). There are increasing concerns on the potential
82 endocrine disrupting effect of these molecules. In this study, we show that among the 10 compounds evaluated,
83 all have an estrogenic activity.

84

85

86 2. Material and methods

87

88 2.1. Materials

89 Actinomycin D, benzophenone (BP), bovin serum albumin (BSA), 17- β -estradiol (E2), 17- α -ethynyl-
90 estradiol (EE2), 2,4-dihydroxy-benzophenone (BP1), genistein (Gen), 2,2',4,4'- tetrahydroxy-benzophenone
91 (BP2), 2-hydroxy-4-methoxy-benzophenone (BP3), 4-hydroxybenzophenone (4BP), 4,4'-dihydroxy-
92 benzophenone (44'BP), 2,3,4-trihydroxy-benzophenone (234BP), 2,3,4,4'-tetrahydroxy-benzophenone
93 (2344'BP), 2,2'-hydroxy-4-methoxy-benzophenone 6 (BP8), 2,4,4'-trihydroxy-benzophenone (THB),
94 progesterone (P4) and testosterone (T) were acquired from Sigma-Aldrich Co.

95

96 2.2. Cell Culture and treatments

97 T47D cells, obtained from ATCC, were routinely maintained in RPMI (Invitrogen, Life technologies,
98 Saint Aubin, France) supplemented with 10% fetal bovine serum, FBS (Biowest, Nuaille, France) and antibiotics
99 containing penicillin, streptomycin and Amphotericin (Invitrogen, Life technologies, Saint Aubin, France) at
100 37°C in 5% CO₂. Before treatment cells were plated in DMEM phenol red-free (Gibco, Life technologies, Saint
101 Aubin, France) containing 5% dextran treated charcoal-stripped FBS (dsFBS) provided by Biowest (Biowest,
102 Nuaille, France). For treatment, 0.1 % ethanol (control) and each compound (E2, EE2, Gen, BP, BP1, BP2, BP3,
103 4BP, 44'BP, 234BP, 2344'BP, BP8, THB, P4 and T) was diluted with DMEM phenol red-free containing 5%
104 dsFBS at the appropriate concentration.

105 2.3. ELISA assay

106 Cells were cultured in 96-well plates containing either 4.10⁴ cells/well in DMEM phenol red-free
107 medium containing 5% of dsFBS. After 24 hours, medium was replaced and cells were then treated with DMEM
108 phenol red free medium with 5% of dsFBS containing the tested molecules during 14 hours. Then, 60 μ l of
109 supernatant were equally diluted with PBS containing 1% BSA. The quantification of CXCL12 secretion was
110 then performed by ELISA (Quantitine kit; R&D Systems, Mineapolis, MN, USA).

111 Then in order to decrease the number of cells used for one experiment and to avoid the intermediate
112 dilution step, several cell density per well were tested. Between 2500 to 40000 cells per well were evaluated.
113 Finally Ten thousands cells per well, cultured in 96-well plate, were chosen for the evaluation of BP estrogenic
114 potency. The medium was then replaced with 100 μ l of DMEM phenol red-free medium containing 5% of
115 dsFBS during 24 hours. Then 100 μ l of DMEM phenol red free containing treatment were added. After 14 hours
116 of incubation, 100 μ l of the supernatant was directly analyzed by ELISA. For each experiment, a standard curve
117 was generated. ELISA was revealed with the CXCL12 DuoSet Elisa kit from R&D Systems. The absorbance at
118 450 and 570 nm was obtained by using a 96-well iMARK Absorbance microplate reader (Biorad, Life Science,
119 Marnes-la-coquette, France).

120 2.4. RT-PCR assays

121 T47D cells were seeded in 6 well-plate in a density at 1.10^5 cells/well in DMEM phenol-red free
122 medium containing 5 % of dsFBS. After 24 hours, cells were treated with 10^{-6} M of each BP and 10^{-8} M of E2
123 and 0.1% ethanol as control during 24 hours. For each treatment, total RNA was extracted with Trizol reagent
124 (Invitrogen) according to supplier's instructions. RNAs were then reverse transcribed in cDNA by MMLV
125 (Promega, Charbonnière, France) using random hexamers (Promega). Quantitative RT-PCR were performed on
126 BioRad MyiQ with iQ Sybr Green Supermix (BioRad, Hercules, CA, USA) using primers for CXCL12, Rev:
127 GCCTCCATGGCATAACATAGG, Fwd: CTCCTGGGGATGTGTAATGG and for GAPDH as control, Rev:
128 GGGCATCCTGGGCTACACTG, Fwd: GAGGTCCACCACCCTGTTGC.

129


130 2.5. Statistics

131 Statistical analyses were performed using Mann and Whitney test on Biostatgv online tool
132 (<http://marne.u707.jussieu.fr/biostatgv/?module=tests>). Differences were considered as significant if p value <
133 0.05.

134 **3. RESULT**

135 3.1. Effect of classical estrogenic compounds on the secretion of CXCL12 in 96 well-plate

136 In previously published method, 24 well-plates were used. By scaling up this method to 96 well-plates,
137 we aimed to screen more conditions during the same experiment. We therefore evaluate the effect of classical
138 estrogenic compounds such as the strong agonist 17- α -ethynyl estradiol (EE2), the natural hormone 17- β -
139 estradiol (E2) and the weak agonist genistein (Gen). Each compound induced an increase of the secretion of
140 CXCL12 when compared to the control ethanol (Fig. 1). E2 and EE2 induced up to 5 to 6-fold increase of
141 CXCL12 secretion. A decrease of the CXCL12 secretion was nevertheless observed for concentration of EE2 up
142 to 10^{-8} M as previously published (Habauzit et al., 2010). Gen also increased the CXCL12 secretion.
143 Consistently with its well described weak agonistic potency, Gen only induced effect at doses higher than 10^{-8}
144 M. The EC₅₀ of each curves was determined and was respectively of 3.15×10^{-13} M for E2, 2.14×10^{-14} M for EE2
145 and 7.17×10^{-8} M for Gen (Table 1). The first effects of molecules on CXCL12 secretion were observed at 10^{-14}
146 M E2 (3 fold increase) and 5×10^{-16} M of EE2 (2-fold increase).




147

148 **Fig. 1: CXCL12 secretion under classical estrogenic compounds stimulation in 96 well plate.**

149

150 3.2. Determination of the optimum number of cells for the ELISA detection without intermediate steps

151 A supernatant dilution step was previously performed to keep the ELISA signal in the linear range of
 152 the calibration curve. In this second step of the method optimization, the intermediary dilution of the supernatant
 153 in PBS 1% BSA was removed by decreasing cell number. Different cell density from 2500 cells/well to 40000
 154 cell/well (Fig. 2) were cultured on 96-well plates. Cells were exposed to 10^{-8} M E2 or ethanol, as control. The
 155 secretion of CXCL12 in 100 μ l of supernatant was monitored and represented as a fold change between exposed
 156 to ethanol and E2 (Fig. 2). The 2×10^4 and 4×10^4 cell numbers permitted to visualize the E2 effect with fold
 157 change of 2.4 compared to the ethanol control. The presence of an equivalent fold change in these two cellular
 158 densities raises the question of the signal saturation, even if for 2×10^4 cells per well, the ELISA is performed in
 159 the linear range of the calibration curve. Therefore 1×10^4 cells per well were preferred. With a fold change of
 160 1.9, this cell number allowed significantly to evaluate the estrogenic potency of compounds without saturation
 161 signal risk.




162
 163 **Fig. 2: CXCL12 secretion depending upon the cell number coated in the 96 well plate and without**
 164 **PBS/BSA intermediary dilution. (*P<0.05, **P<0.01, ***P<0.005)**

165
 166 3.3. Specificity of the estrogenic sensitivity of the CXCL12 secretion

167 Two well-known endocrine compounds with non-estrogenic activity were tested on the ability to induce
 168 the CXCL12 secretion. These two compounds were the male hormone testosterone (T) and the women menstrual
 169 and pregnancy hormone progesterone (P4). The stimulation by a dose effect of these two compounds did not

170 modify the secretion of the CXCL12 (Fig. 3). Altogether these results evidenced that the response is specific to
171 estrogenic stimulation.



172

Fig. 3: Assessment of the estrogenic properties of dose effect of A) testosterone (T) and B) progesterone (P4) by CXCL-test

173

174 3.4. Use of the optimized CXCL-test for the assessment of estrogenic potency of Benzophenones

175 According to our developed ELISA method, all 10 tested benzophenones exhibit estrogenic properties


176 in a dose-dependent manner (Fig.4). Nevertheless, among these 10 molecules, two groups of estrogenic

177 compounds can be delineated. The first one contains 6 compounds (BP, BP1, BP2, BP3, 234BP and 2344'BP)

178 that have a weak estrogenic activity with EC50 near 10^{-5} M (table 1). The only active dose is 10^{-5} M and the
179 maximum response is lesser than 70% of E2 effect. The 4 last compounds (4BP, 44'BP, BP8 and THB) have
180 medium estrogenic properties with active concentration from 10^{-6} M and the maximum response is between 80%
181 and 110% of E2 effect. The most powerful estrogenic compounds are 44'BP (near 100% of E2 effect) and BP8
182 (110% of E2 effect).

Compounds	EC50 (M)
E2	3.15×10^{-13}
EE2	2.14×10^{-14}
Gen	7.18×10^{-8}
BP	1.09×10^{-5}
BP1	9.46×10^{-6}
BP2	8.29×10^{-6}
BP3	9.93×10^{-6}
4BP	9.45×10^{-7}
44'BP	6.7×10^{-7}
234BP	7×10^{-6}
2344'BP	8.42×10^{-6}
BP8	1.5×10^{-6}
THB	5.24×10^{-7}

183 Table 1: EC50 of each compound used in the evaluation.



184

185 **Fig. 4: Assessment of estrogenic properties of different doses of benzophenones (BP, BP1, BP2, BP3, 4BP,**

186 **44'BP, 234BP, 2344'BP, BP8 and THB) using CXCL-test.**


187

188 3.4. Validation of CXCL-test by quantitative PCR

189 To confirm that stimulation of CXCL12 secretion by BPs is only due to the stimulation of gene
190 expression and not to a transient increase of CXCL12 protein release by action on exocytose, RT-qPCR method
191 was also used. After 24 hours of 10^{-6} M BP treatments, T47D RNA were extracted and then analyzed by qPCR.
192 As shown in Fig. 5A, *CXCL12* mRNA obtained after 24 hours of treatment correlated very well with CXCL12
193 secretion obtained after 14 hours of treatment. The Pearson correlation is 84.15% with a $p < 0.001$. Of note is
194 that at 10^{-6} M, BP molecule did not show estrogenic activity in both assays while 4BP and BP8 were among the
195 most powerful estrogenic compounds. The differences observed between qPCR and ELISA approaches are
196 likely due to the treatment time as well as the sensitivity of the method.

197 To further investigate whether or not the effect of BPs on CXCL12 release is directly dependent on
198 CXCL12 gene transcriptional activity, T47D cells were treated with different doses of BPs, in presence of an
199 inhibitor of the transcription, the actinomycine D. As shown in Fig. 5B, Actinomycin D inhibited the BP-
200 dependent CXCL12 secretion for both E2 and BP molecules at their effective doses (10^{-6} M or 10^{-5} M). No
201 transcriptional independent release of CXCL12 was observed and no significant differences between control
202 ethanol and BP treatments were observed. The BP-dependent CXCL12 secretion is therefore due to the
203 estrogenic effect of molecules and not of an increase in CXCL12 release in cell supernatant.

204



205

206 **Fig. 5: A) Evolution of CXCL12 secretion and *CXCL12* expression measured respectively by ELISA and**

207 **qPCR after stimulation with E2 at 10⁻⁸ M and benzophenones at 10⁻⁶ M. B) CXCL-test performed on cells**

208 **treated or not with control ethanol, E2 and effective doses of benzophenones with or without actinomycin**

209 **D.**

210

211

212 4. DISCUSSION

213 Since decades several methods have been developed for the evaluation and the quantification of
214 endocrine disrupting chemicals, using their ability to induce proliferation, expression of reporter genes or
215 endogenous genes or any other characteristics of these compounds (Kerdivel et al., 2013a; Leusch, 2008; Scholz
216 et al., 2013). These methods used (i) whole animal with uterotrophic test in mouse (Isenhower et al., 1986) or
217 vitellogenin test in fish (Flouriot et al., 1995), (ii) cell-based *in vitro* assays such as proliferation test (Soto et al.,
218 1986), differentiation test (Habauzit et al., 2014) or reporter assays and (iii) molecular *in vitro* assay with
219 receptor binding assay (Habauzit et al., 2008). Each of these methods has their own advantages such as
220 integrated response, physiological response, specific response or fast response. Here we have aimed to optimize
221 the CXCL-test in order to increase the number of molecules to be tested in a single assay. We also evidenced the
222 low detection limit of the CXCL-test and that the use of natural endogenous gene expression could be an early
223 indicator of the proliferation capacity of a molecule. This development opens the possibility to use this test as a
224 high throughput assay for estrogenic compounds screening. This method is fast and alternative to animal test in
225 agreement with REACH program (Lombardo et al., 2014a, 2014b). At the moment, one of the main methods
226 used for evaluation of xeno-estrogens properties of chemicals is the ER-positive cell line proliferation test based
227 on Soto et al. work which was originally developed on T47D cell line (Soto et al., 1986). The CXCL-test is a
228 method that allows fast assessment of the estrogen-like action of endocrine disruptors. This test constitutes an
229 alternative for proliferative test (14 hours *versus* 5 days) of ER-positive cell lines (such as MCF7 or T47D)
230 (Habauzit et al., 2010). This test relied on the ability of estrogens to induce the expression and the secretion of
231 CXCL12 in ER-positive cells which has been demonstrated in many tissues and cancers (Boudot et al., 2014;
232 Roberti et al., 2012). CXCL12 and its two G-coupled receptors CXCR4 and CXCR7 are involved in the
233 proliferation of ER-positive cancer cells (Boudot et al. 2011), and is also a marker of the breast cancer
234 progression (Boudot et al. 2014). Indeed, when breast cancer cell progress they lose the estrogenic sensitivity,
235 the decrease of the local CXCL12 secretion induces EMT and metastasis (Boudot et al., 2014; Roberti et al.,
236 2012). In this article, we proposed key parameters that should be considered for test improvement. First of all,
237 we intended to increase the number of tested molecules at the same time by adapting the method to the 96 well
238 plates. By screening the classical estrogenic compounds E2, EE2 and Gen, the reproducibility of the method was
239 checked with our previously data (Habauzit et al., 2010). Secondly, in order to avoid the intermediate dilution of
240 the supernatant, the number of cells was decreased to 10000 cells per well. The final method greatly decreases

241 the time and steps needed for the global evaluation of the estrogenic potency of a large number of compounds.
242 Finally, when compared to the classically used proliferation test, our optimized CXCL-test allows an easier
243 interpretation of the results and the saving of time is really significant even if this test could exhibit a slightly
244 more expensive cost. These kinds of fast and accurate detection methods are clearly important for risk
245 assessment, considering the constant increase of new chemicals released in the environment.

246 Altogether, these optimized conditions were used for the screening of the benzophenone derivatives that
247 are emerging endocrine disruptors. These molecules are present in some cosmetics and are found in many
248 surface waters around the world with an environmental concentration from ng/L to µg/L (Jurado et al., 2014;
249 Loraine and Pettigrove, 2006; Molins-Delgado et al., 2016). These compounds began to be increasingly studied
250 because of their potential risk for human and wildlife (Kim and Choi, 2014).

251 All tested BPs exhibit estrogen-like activity with various potencies. Indeed, BP, BP1, BP2, BP3, 234BP
252 and 2344'BP showed a weak estrogenic potency even at 10^{-5} M. Surprisingly, the BP molecule showed a weak
253 but detectable estrogenic activity in inducing CXCL12 secretion. However our previous docking analysis
254 suggested no direct interaction with ER ligand-binding domain (Kerdivel et al., 2013b). This low estrogenic
255 activity of BP molecule observed at 10^{-5} M is probably due to its conversion in 4BP in cell culture (Hayashi et
256 al., 2006; Nakagawa et al., 2000). On the other hand, 4BP, 44'BP, BP8 and THB showed much more potent
257 estrogenic activity inducing a response from 10^{-6} M. Among these compounds, 4BP and BP8 were also
258 described as the most potent estrogenic compounds, in regards to previously published results on estrogen-
259 sensitive reporter assays and on the expression of the *CXCL12* gene in MCF7 cell lines (Kerdivel et al., 2013b).
260 The difference in the estrogenic sensitivity is probably due to the ER α /ER β ratio which is different in MCF7 and
261 T47D cells. Our previously published data have also evidenced that T47D cells are more sensitive to estrogenic
262 stimulation than MCF7 especially for genistein (Habauzit et al., 2010). Moreover, ER β stably expressed in Hela
263 cells (HELN ER β assay) exhibited much more sensitivity than ER α for several benzophenones such as BP1,
264 BP2 and THB (Molina-Molina et al., 2008).

265 Under benzophenone treatments, stimulations of the *CXCL12* mRNA expression and protein secretion
266 were nearly identical with a correlation of more than 80%. This was also demonstrated by the actinomycin D
267 treatments, showing that the increase of CXCL12 secretion is only due to the increase of *CXCL12* expression
268 and not to an increase of CXCL12 release in the supernatant by BP-induced exocytosis. However, because of the

269 duration of treatment (14 hours for secretion and 24 hours for the qPCR) and technique sensitivity, some
270 differences in the amplitude of response were observed. Here we evaluated only the short-term effect of these
271 molecules. However, the benzophenone endocrine activity is currently under question especially about the
272 potential transgenerational effects. For instance, a recent study showed that BP3 has adverse effects in Japanese
273 medaka and some transgenerational disrupting effects in hormonal balance and reproductive function may be
274 noticed when fish were exposure at the level of $\mu\text{g} / \text{L}$ to BP3 (Kim et al., 2014).

275

276 **5. CONCLUSION**

277 Today thousand chemicals are currently used in common human life without knowing their endocrine
278 disrupting status. Among the number of methods that have been developed last decades, the CXCL-test promotes
279 a very low detection limit for well-known estrogenic compounds E2 and EE2, and used a natural and
280 untransformed gene that is involved in the proliferation and the migration of the breast cancer cells. In this study,
281 we described the optimization of CXCL-test that permits fast and reliable evaluation of the estrogenic potencies
282 of environmental chemicals. We used this optimized test to evaluate the EDC activity of some benzophenone
283 derivatives. These compounds present in environment in high concentration have an estrogenic activity and
284 constitute a risk for human and wildlife.

285

286 **Acknowledgements**

287 Authors are grateful to Dr. Frederic Leusch for its help and advices during the evaluation of this article. This
288 work was supported by funds from the French Ministry of Ecology, Energy and Sustainable Development
289 (PNRPE). We also thank CNRS, INSERM and the University of Rennes 1 for supporting our research.

290 **Conflict of interest**

291 The authors declare that they have no conflict of interest.

292

293 **BIBLIOGRAPHY**

294 Boudot, A., Kerdivel, G., Habauzit, D., Eeckhoutte, J., Le Dily, F., Flouriot, G., Samson, M., Pakdel, F., 2011.
 295 Differential estrogen-regulation of CXCL12 chemokine receptors, CXCR4 and CXCR7, contributes to
 296 the growth effect of estrogens in breast cancer cells. *PLoS One* 6, e20898.
 297 doi:10.1371/journal.pone.0020898

298 Boudot, A., Kerdivel, G., Lecomte, S., Flouriot, G., Desille, M., Godey, F., Leveque, J., Tas, P., Le Dréan, Y.,
 299 Pakdel, F., 2014. COUP-TFI modifies CXCL12 and CXCR4 expression by activating EGF signaling
 300 and stimulates breast cancer cell migration. *BMC Cancer* 14, 407. doi:10.1186/1471-2407-14-407

301 Flouriot, G., Pakdel, F., Ducouret, B., Valotaire, Y., 1995. Influence of xenobiotics on rainbow trout liver
 302 estrogen receptor and vitellogenin gene expression. *J. Mol. Endocrinol.* 15, 143–151.

303 Gago-Ferrero, P., Díaz-Cruz, M.S., Barceló, D., 2011. Fast pressurized liquid extraction with in-cell purification
 304 and analysis by liquid chromatography tandem mass spectrometry for the determination of UV filters
 305 and their degradation products in sediments. *Anal. Bioanal. Chem.* 400, 2195–2204.
 306 doi:10.1007/s00216-011-4951-1

307 Glace, L., Grygielko, E.T., Boyle, R., Wang, Q., Laping, N.J., Sulpizio, A.C., Bray, J.D., 2009. Estrogen-
 308 induced stromal cell-derived factor-1 (SDF-1/Cxcl12) expression is repressed by progesterone and by
 309 Selective Estrogen Receptor Modulators via estrogen receptor alpha in rat uterine cells and tissues.
 310 *Steroids* 74, 1015–1024. doi:10.1016/j.steroids.2009.07.011

311 Habauzit, D., Armengaud, J., Roig, B., Chopineau, J., 2008. Determination of estrogen presence in water by SPR
 312 using estrogen receptor dimerization. *Anal. Bioanal. Chem.* 390, 873–883. doi:10.1007/s00216-007-
 313 1725-x

314 Habauzit, D., Boudot, A., Kerdivel, G., Flouriot, G., Pakdel, F., 2010. Development and validation of a test for
 315 environmental estrogens: Checking xeno-estrogen activity by CXCL12 secretion in BREAST
 316 CANCER CELL LINES (CXCL-test). *Environ. Toxicol.* 25, 495–503. doi:10.1002/tox.20594

317 Habauzit, D., Chopineau, J., Roig, B., 2007. SPR-based biosensors: a tool for biodetection of hormonal
 318 compounds. *Anal. Bioanal. Chem.* 387, 1215–1223. doi:10.1007/s00216-006-0958-4

319 Habauzit, D., Ferrière, F., Botharel, N., Flouriot, G., Pakdel, F., Saligaut, C., 2014. Differentiation of PC12 cells
 320 expressing estrogen receptor alpha: a new bioassay for endocrine-disrupting chemicals evaluation.
 321 *Chemosphere* 112, 240–247. doi:10.1016/j.chemosphere.2014.03.101

322 Hall, J.M., Korach, K.S., 2013. Endocrine disrupting chemicals promote the growth of ovarian cancer cells via
 323 the ER-CXCL12-CXCR4 signaling axis. *Mol. Carcinog.* 52, 715–725. doi:10.1002/mc.21913

324 Hall, J.M., Korach, K.S., 2003. Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates
 325 the mitogenic effects of estradiol in ovarian and breast cancer cells. *Mol. Endocrinol. Baltim. Md* 17,
 326 792–803. doi:10.1210/me.2002-0438

327 Hayashi, T., Okamoto, Y., Ueda, K., Kojima, N., 2006. Formation of estrogenic products from benzophenone
 328 after exposure to sunlight. *Toxicol. Lett.* 167, 1–7. doi:10.1016/j.toxlet.2006.08.001

329 Isenhower, W.D., Newbold, R.R., Cefalo, R.C., Korach, K.S., McLachlan, J.A., 1986. Absence of estrogenic
 330 activity in some drugs commonly used during pregnancy. *Biol. Res. Pregnancy Perinatol.* 7, 6–10.

331 Jurado, A., Gago-Ferrero, P., Vázquez-Suñé, E., Carrera, J., Pujades, E., Díaz-Cruz, M.S., Barceló, D., 2014.
 332 Urban groundwater contamination by residues of UV filters. *J. Hazard. Mater.* 271, 141–149.
 333 doi:10.1016/j.jhazmat.2014.01.036

334 Kerdivel, G., Habauzit, D., Pakdel, F., 2013a. Assessment and molecular actions of endocrine-disrupting
 335 chemicals that interfere with estrogen receptor pathways. *Int. J. Endocrinol.* 2013, 501851.
 336 doi:10.1155/2013/501851

337 Kerdivel, G., Le Guevel, R., Habauzit, D., Brion, F., Ait-Aissa, S., Pakdel, F., 2013b. Estrogenic potency of
 338 benzophenone UV filters in breast cancer cells: proliferative and transcriptional activity substantiated
 339 by docking analysis. *PLoS One* 8, e60567. doi:10.1371/journal.pone.0060567

340 Kim, S., Choi, K., 2014. Occurrences, toxicities, and ecological risks of benzophenone-3, a common component
 341 of organic sunscreen products: a mini-review. *Environ. Int.* 70, 143–157.
 342 doi:10.1016/j.envint.2014.05.015

343 Kim, S., Jung, D., Kho, Y., Choi, K., 2014. Effects of benzophenone-3 exposure on endocrine disruption and
 344 reproduction of Japanese medaka (*Oryzias latipes*)--a two generation exposure study. *Aquat. Toxicol.*
 345 *Amst. Neth.* 155, 244–252. doi:10.1016/j.aquatox.2014.07.004

346 Leusch, F., 2008. Tools to Detect Estrogenic Activity in Environmental Waters., Global Water Research
 347 Coalition 2008.

348 Lombardo, A., Roncaglioni, A., Benfenati, E., Nendza, M., Segner, H., Jeram, S., Pauné, E., Schüürmann, G.,
 349 2014a. Optimizing the aquatic toxicity assessment under REACH through an integrated testing strategy
 350 (ITS). *Environ. Res.* 135, 156–164. doi:10.1016/j.envres.2014.09.002

351 Lombardo, A., Roncaglioni, A., Benfentati, E., Nendza, M., Segner, H., Fernández, A., Kühne, R., Franco, A.,
352 Pauné, E., Schüürmann, G., 2014b. Integrated testing strategy (ITS) for bioaccumulation assessment
353 under REACH. *Environ. Int.* 69, 40–50. doi:10.1016/j.envint.2014.04.005
354 Loraine, G.A., Pettigrove, M.E., 2006. Seasonal variations in concentrations of pharmaceuticals and personal
355 care products in drinking water and reclaimed wastewater in southern California. *Environ. Sci. Technol.*
356 40, 687–695.
357 Molina-Molina, J.-M., Escande, A., Pillon, A., Gomez, E., Pakdel, F., Cavaillès, V., Olea, N., Ait-Aïssa, S.,
358 Balaguer, P., 2008. Profiling of benzophenone derivatives using fish and human estrogen receptor-
359 specific in vitro bioassays. *Toxicol. Appl. Pharmacol.* 232, 384–395. doi:10.1016/j.taap.2008.07.017
360 Molins-Delgado, D., Díaz-Cruz, M.S., Barceló, D., 2016. Ecological risk assessment associated to the removal
361 of endocrine-disrupting parabens and benzophenone-4 in wastewater treatment. *J. Hazard. Mater.* 310,
362 143–151. doi:10.1016/j.jhazmat.2016.02.030
363 Nakagawa, Y., Suzuki, T., Tayama, S., 2000. Metabolism and toxicity of benzophenone in isolated rat
364 hepatocytes and estrogenic activity of its metabolites in MCF-7 cells. *Toxicology* 156, 27–36.
365 Pattarozzi, A., Gatti, M., Barbieri, F., Würth, R., Porcile, C., Lunardi, G., Ratto, A., Favoni, R., Bajetto, A.,
366 Ferrari, A., Florio, T., 2008. 17beta-estradiol promotes breast cancer cell proliferation-inducing stromal
367 cell-derived factor-1-mediated epidermal growth factor receptor transactivation: reversal by gefitinib
368 pretreatment. *Mol. Pharmacol.* 73, 191–202. doi:10.1124/mol.107.039974
369 Roberti, M.P., Arriaga, J.M., Bianchini, M., Quintá, H.R., Bravo, A.I., Levy, E.M., Mordoh, J., Barrio, M.M.,
370 2012. Protein expression changes during human triple negative breast cancer cell line progression to
371 lymph node metastasis in a xenografted model in nude mice. *Cancer Biol. Ther.* 13, 1123–1140.
372 doi:10.4161/cbt.21187
373 Rodríguez-Gómez, R., Jiménez-Díaz, I., Zafra-Gómez, A., Ballesteros, O., Navalón, A., 2014. A multiresidue
374 method for the determination of selected endocrine disrupting chemicals in human breast milk based on
375 a simple extraction procedure. *Talanta* 130, 561–570. doi:10.1016/j.talanta.2014.07.047
376 Scholz, S., Renner, P., Belanger, S.E., Busquet, F., Davi, R., Demeneix, B.A., Denny, J.S., Léonard, M.,
377 McMaster, M.E., Villeneuve, D.L., Embry, M.R., 2013. Alternatives to in vivo tests to detect endocrine
378 disrupting chemicals (EDCs) in fish and amphibians--screening for estrogen, androgen and thyroid
379 hormone disruption. *Crit. Rev. Toxicol.* 43, 45–72. doi:10.3109/10408444.2012.737762
380 Soto, A.M., Murai, J.T., Siiteri, P.K., Sonnenschein, C., 1986. Control of cell proliferation: evidence for negative
381 control on estrogen-sensitive T47D human breast cancer cells. *Cancer Res.* 46, 2271–2275.
382 Soto, A.M., Sonnenschein, C., Chung, K.L., Fernandez, M.F., Olea, N., Serrano, F.O., 1995. The E-SCREEN
383 assay as a tool to identify estrogens: an update on estrogenic environmental pollutants. *Environ. Health*
384 *Perspect.* 103 Suppl 7, 113–122.
385 Tsui, M.M.P., Leung, H.W., Wai, T.-C., Yamashita, N., Taniyasu, S., Liu, W., Lam, P.K.S., Murphy, M.B.,
386 2014. Occurrence, distribution and ecological risk assessment of multiple classes of UV filters in
387 surface waters from different countries. *Water Res.* 67, 55–65. doi:10.1016/j.watres.2014.09.013
388 Vela-Soria, F., Ballesteros, O., Zafra-Gómez, A., Ballesteros, L., Navalón, A., 2014. A multiclass method for the
389 analysis of endocrine disrupting chemicals in human urine samples. Sample treatment by dispersive
390 liquid-liquid microextraction. *Talanta* 129, 209–218. doi:10.1016/j.talanta.2014.05.016
391 Yoon, K., Kwack, S.J., Kim, H.S., Lee, B.-M., 2014. Estrogenic endocrine-disrupting chemicals: molecular
392 mechanisms of actions on putative human diseases. *J. Toxicol. Environ. Health B Crit. Rev.* 17, 127–
393 174. doi:10.1080/10937404.2014.882194
394
395